EGFR and lung carcinoma: The occurrence of mutations in EGFR and KRAS, which encodes a GTPase downstream of EGFR (see above), is mutually exclusive in lung cancers and they exhibit many contrasting characteristics such as clinical background, pathological features of patients harboring each mutation, and prognostic or predictive implications.